{"id":"NCT02343458","sponsor":"Pearl Therapeutics, Inc.","briefTitle":"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD","officialTitle":"A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-30","primaryCompletion":"2017-08-31","completion":"2017-08-31","firstPosted":"2015-01-22","resultsPosted":"2019-02-20","lastUpdate":"2019-02-20"},"enrollment":1756,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"GFF MDI (PT003)","otherNames":["Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol"]},{"type":"DRUG","name":"FF MDI (PT005)","otherNames":["Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol"]},{"type":"DRUG","name":"GP MDI (PT001)","otherNames":["Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol"]},{"type":"DRUG","name":"Placebo MDI","otherNames":["Placebo (matching) for GFF MDI, FF MDI, and GP MDI"]}],"arms":[{"label":"GFF MDI (PT003)","type":"EXPERIMENTAL"},{"label":"FF MDI (PT005)","type":"EXPERIMENTAL"},{"label":"GP MDI (PT001)","type":"EXPERIMENTAL"},{"label":"Placebo MDI","type":"PLACEBO_COMPARATOR"}],"summary":"A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI; PT003), FF MDI; PT005, and GP MDI; PT001) in subjects with moderate to very severe COPD, compared with placebo.","primaryOutcome":{"measure":"Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach)","timeFrame":"at week 24","effectByArm":[{"arm":"GFF MDI 14.4/9.6 ug","deltaMin":120,"sd":null},{"arm":"FF MDI 9.6 ug","deltaMin":47,"sd":null},{"arm":"GP MDI 14.4 ug","deltaMin":60,"sd":null},{"arm":"Placebo MDI","deltaMin":-45,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":166,"countries":["United States","China","Czechia","Germany","Hungary","Japan","Poland","Russia","South Korea","Taiwan","United Kingdom"]},"refs":{"pmids":["35815359","32450869","32021148","32021143"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4150&filename=PT003014%20Statistical%20Analysis%20Plan%2011_01_01%20_Redacted%20updated%2020181003%20PDFA.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4150&filename=PT003014-05-%20CLINICAL%20STUDY%20PROTOCOL%20Redacted_updated%2020181003%20PDFA.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4150&filename=PT003014-05-%20CLINICAL%20STUDY%20PROTOCOL%20Redacted%20PDFA.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4150&filename=PT003014%20Statistical%20Analysis%20Plan%20PDFA.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":53,"n":551},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Chronic obstructive pulmonary disease","Cough","Dyspnoea"]}}